RCM Technologies, Inc. (NASDAQ:RCMT) Q1 2022 Earnings Conference Call April 28, 2022 10:00 AM ET

Company Participants

Kevin Miller - Chief Financial Officer

Brad Vizi - Executive Chairman

Conference Call Participants

Bill Sutherland - The Benchmark Company

Min Cho - B. Riley Securities

Frank Kelly - Scopia Capital

Operator

Good morning, and thank you for joining us. This is Kevin Miller, Chief Financial Officer of RCM Technologies. I am joined today by Brad Vizi, RCM’s Executive Chairman. Our presentation in this call will contain forward-looking statements. The information contained in the forward-looking statements is based on our beliefs, estimates, and assumptions and information currently available to us and these matters may materially change in the future.

Many of these beliefs, estimates, and assumptions are subject to rapid changes. For more information on our forward-looking statements and the risks, uncertainties, and other factors to which they are subject, please see the periodic reports on Forms 10-K, 10-Q, and 8-K that we file with the SEC, as well as our press releases that we issue from time to time.

I will now turn the call over to Brad Vizi, Executive Chairman, to provide an overview of RCM’s operating performance during the quarter.

Brad Vizi

Thanks, Kevin. Good morning, everyone. RCM’s first quarter results demonstrate a strong start to 2022 as we continue to build on the foundation we've established and drive execution across each of our business units. We also expect continued strength from each of our divisions with every member of our team steadfast in their commitment, delivering excellence to our clients each and every day.

Once again, all of our units performed well during the quarter. Our engineering team is seeing robust activity across the board. Our healthcare services team continues to expand its client footprint fortifying its presence as the premier service provider for school districts across the country.

Lastly, our life sciences and IT group is making demonstrable strides toward becoming a leading solutions and managed service provider to the Life Sciences end market. I will speak to several of the operational highlights in a moment, but first, I want to thank the team for a job well done and their commitment to propelling RCM to the next level. As proud as I am of the team's historical performance, we must continue to remind ourselves that we are still in the early stages of unlocking the massive potential of our platform.